Arkema shares are sitting close to an important technical support area around 96.88 EUR based on weekly price data. Against this backdrop, investors can use this good timing for new long positions. Investors have an opportunity to buy the stock and target the € 104.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
The share is getting closer to its long-term support in weekly data, at EUR 96.88, which offers good timing for buyers.
Predictions on business development from analysts polled by Thomson-Reuters are tight. This results from either a good visibility into core activities or accurate earnings releases.
Historically, the company has been releasing figures that are above expectations.
The company's attractive earnings multiples are brought to light by a P/E ratio at 11.76 for the current year.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.